AUS
NZ
UK
CA
USA
IND
Highlights
- Avecho Biotechnology (ASX:AVE) teams up with Sandoz Group for a CBD-based insomnia treatment.
- Nearly 9.5 million Australians suffer from insomnia, creating a significant commercial opportunity.
- Avecho to receive up to $25.7 million in milestone payments and tiered royalties of 14%-19%.
Avecho Biotechnology (ASX:AVE) has entered into a 10-year exclusive development and licensing agreement with Swiss pharmaceutical company Sandoz Group to explore the commercialization of a cannabidiol (CBD) capsule for insomnia in Australia. This strategic partnership aims to address a widespread issue affecting millions of Australians while tapping into a market with an estimated sales potential of over $200 million annually.
With nearly 9.5 million Australians experiencing insomnia symptoms and around 3.6 million facing chronic sleep disturbances, the demand for effective treatment options continues to grow. Through this collaboration, Avecho and Sandoz seek to introduce a pharmaceutical-grade CBD capsule as an over-the-counter solution, pending regulatory approval from the Therapeutic Goods Administration (TGA).
Australian Market Expansion
Under the agreement, Sandoz gains the potential to secure exclusive Australian commercial rights to Avecho’s Phase III CBD capsule. While Avecho retains the rights to market the product globally, Sandoz has been granted the first right of refusal for expansion into other territories.
To solidify this deal, Sandoz has committed to an upfront licensing fee of approximately $4.8 million. Meanwhile, Avecho remains responsible for funding and overseeing the ongoing Phase III clinical trial to ensure the product’s success in the Australian market.
Financial and Commercial Potential
Avecho CEO Dr. Paul Gavin highlighted the significance of this collaboration, emphasizing the commercial strength of the company's drug delivery platform and its potential to transform insomnia treatment. He also pointed to Sandoz’s strong market presence, which will play a key role in making the CBD capsule widely accessible to Australian consumers.
In addition to the initial licensing payment, Avecho stands to receive up to $25.7 million in development milestone payments before commercialization. Once the product enters the market, Avecho will earn tiered royalties between 14% and 19% based on net sales, ensuring a sustainable long-term revenue stream.
Marketing, Distribution, and Future Growth
As part of the agreement, Sandoz plans to purchase the finished product from Avecho and take charge of its commercialization, including marketing and distribution efforts in Australia.
The deal is structured for long-term collaboration, with an initial term of 10 years. It also includes automatic extensions for two additional two-year terms unless both parties decide otherwise.
This partnership not only strengthens Avecho’s position in the CBD pharmaceuticals space but also presents a compelling opportunity to address a major health concern in Australia with a scientifically backed, market-ready solution.
